Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer
Authors:
Open Access
- 11 February 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 11 (7) , 1605-1616
Abstract
Background: Pancreatic cancer is one of the most prothrombotic cancers. Among patients receiving preoperative chemotherapy followed by surgery, chemotherapy and surgery represent a compound risk for venous thromboembolism (VTE), rendering the postoperative time a period of interest. We aimed to analyze whether preoperative oncologic therapy increases the risk for VTE after surgery and identify which characteristics associate with VTE.Methods: We first identified patients surgically treated for pancreatic cancer at Helsinki University Hospital between 2000 and 2017, collecting the following data: gender, age at surgery, preoperative medication, body mass index (BMI), preoperative chemo(radio)therapy, tumor size, positive node ratio, perineural and perivascular invasion, tumor grade, surgical technique, postoperative anticoagulation, adjuvant therapy, time of VTE, time of local disease recurrence, time of distant metastasis, and time of death. With a follow‐up period of at least 2 years or until death, we compared a total of 93 preoperative oncologic therapy and 291 upfront surgery patients (n = 384, median age 66.5 years).Results: Preoperative oncologic therapy increased the risk for thrombosis after surgery (hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.03–2.53). The VTE incidence rate remained high for up to 2 years after surgery. BMI ≥30 kg/m2, prior anticoagulation, and disease recurrence (p < 0.05, respectively) associated with VTE. VTE is also associated with shorter overall survival (HR 3.25; 95% CI 2.36–4.44). In 71.6% (95% CI 60.5–81.1) of patients, VTE was diagnosed after disease recurrence.Conclusions: Preoperative oncologic therapy represents an independent risk factor for VTE, not only during the immediate postoperative period but up to 2 years after surgery. VTE is associated with obesity, prior anticoagulation, and disease recurrence and diminishes overall survival.Keywords
Funding Information
- Sigrid Juséliuksen Säätiö
- Syöpäsäätiö
- Mary och Georg C. Ehrnrooths Stiftelse
- Suomen Kulttuurirahasto
This publication has 47 references indexed in Scilit:
- Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patientsBlood, 2013
- Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis StudyHaematologica, 2013
- Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United StatesCancer, 2012
- Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-AnalysisPLOS Medicine, 2012
- Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006British Journal of Cancer, 2010
- Epidemiology and pathophysiology of cancer-associated thrombosisBritish Journal of Cancer, 2010
- Cancer-Associated Thrombosis~!2009-11-10~!2009-12-11~!2010-02-22~!The Open Cardiovascular Medicine Journal, 2010
- High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Assessing Risk of Venous Thromboembolism in the Patient With CancerJournal of Clinical Oncology, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008